Carisma Therapeutics (CARM) Competitors

$0.0001 0.00 (0.00%)

As of 05/15/2026 03:49 PM Eastern

CARM vs. EVGN, SCPS, VRPX, VAXX, and ARDS

Should you buy Carisma Therapeutics stock or one of its competitors? MarketBeat compares Carisma Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carisma Therapeutics include Evogene (EVGN), Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Vaxxinity (VAXX), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "medical" sector.

How does Carisma Therapeutics compare to Evogene?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Evogene has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Evogene currently has a consensus target price of $3.50, suggesting a potential upside of 377.82%. Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.66	-$8.48M	-$1.17	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Evogene has a net margin of -214.57% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-214.57%	-121.44%	-57.34%
Carisma Therapeutics	-254.28%	N/A	-192.17%

10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.62 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Positive
Carisma Therapeutics	Neutral

Summary

Evogene beats Carisma Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Scopus BioPharma has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Carisma Therapeutics has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Scopus BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

44.3% of Carisma Therapeutics shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Carisma Therapeutics	Neutral

Summary

Carisma Therapeutics beats Scopus BioPharma on 8 of the 11 factors compared between the two stocks.

How does Carisma Therapeutics compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Carisma Therapeutics (NASDAQ:CARM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Virpax Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Virpax Pharmaceuticals has a beta of 2.56, indicating that its share price is 156% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Virpax Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virpax Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Carisma Therapeutics beats Virpax Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Vaxxinity?

Carisma Therapeutics (NASDAQ:CARM) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Vaxxinity has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Vaxxinity	N/A	N/A	N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vaxxinity has lower revenue, but higher earnings than Carisma Therapeutics. Vaxxinity is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

Carisma Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, indicating that its share price is 7,537% less volatile than the broader market.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Vaxxinity	Neutral

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Carisma Therapeutics beats Vaxxinity on 8 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Carisma Therapeutics (NASDAQ:CARM) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Aridis Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Aridis Pharmaceuticals	N/A	N/A	N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00

Carisma Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, indicating that its share price is 4,837% more volatile than the broader market.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Aridis Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aridis Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Carisma Therapeutics beats Aridis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4K	$3.04B	$6.42B	$12.48B
Dividend Yield	N/A	1.96%	2.80%	5.25%
P/E Ratio	0.00	17.11	20.38	25.24
Price / Sales	0.00	303.32	566.15	82.24
Price / Cash	N/A	57.86	43.04	56.04
Price / Book	0.00	4.33	9.87	6.90
Net Income	-$60.48M	$72.19M	$3.57B	$334.66M
7 Day Performance	N/A	-3.06%	0.31%	0.13%
1 Month Performance	N/A	-3.05%	-1.27%	1.11%
1 Year Performance	N/A	36.81%	33.54%	30.62%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	2.3715 of 5 stars	$0.00 flat	$1.00 +999,900.0%	-99.9%	$4K	$10.77M	0.00	20
EVGN Evogene	2.4761 of 5 stars	$0.76 -2.0%	$3.50 +359.9%	-40.4%	$6.77M	$3.85M	N/A	140	Upcoming Earnings Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$25K	N/A	N/A	9	Gap Up
VRPX Virpax Pharmaceuticals	N/A	$0.01 +2,120.0%	N/A	-99.8%	$14K	N/A	N/A	7
VAXX Vaxxinity	N/A	$0.00 flat	N/A	-99.0%	$13K	N/A	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SCPS, VRPX, VAXX, and ARDS

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Scopus BioPharma?

Summary

How does Carisma Therapeutics compare to Virpax Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Vaxxinity?

Summary

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, SCPS, VRPX, VAXX, and ARDS

How does Carisma Therapeutics compare to Evogene?

Which has more volatility and risk, EVGN or CARM?

Do analysts prefer EVGN or CARM?

Which has stronger earnings & valuation, EVGN or CARM?

Is EVGN or CARM more profitable?

Do institutionals & insiders hold more shares of EVGN or CARM?

Does the media refer more to EVGN or CARM?

Summary

How does Carisma Therapeutics compare to Scopus BioPharma?

Which has more risk and volatility, SCPS or CARM?

Do analysts recommend SCPS or CARM?

Which has better valuation and earnings, SCPS or CARM?

Is SCPS or CARM more profitable?

Do institutionals and insiders believe in SCPS or CARM?

Does the media favor SCPS or CARM?

Summary

How does Carisma Therapeutics compare to Virpax Pharmaceuticals?

Do insiders & institutionals believe in VRPX or CARM?

Does the media favor VRPX or CARM?

Which has preferable earnings and valuation, VRPX or CARM?

Which has more volatility & risk, VRPX or CARM?

Is VRPX or CARM more profitable?

Do analysts recommend VRPX or CARM?

Summary

How does Carisma Therapeutics compare to Vaxxinity?

Is CARM or VAXX more profitable?

Do insiders and institutionals have more ownership in CARM or VAXX?

Which has stronger valuation and earnings, CARM or VAXX?

Which has more volatility and risk, CARM or VAXX?

Does the media refer more to CARM or VAXX?

Do analysts prefer CARM or VAXX?

Summary

How does Carisma Therapeutics compare to Aridis Pharmaceuticals?

Is CARM or ARDS more profitable?

Do insiders and institutionals have more ownership in CARM or ARDS?

Which has stronger valuation and earnings, CARM or ARDS?

Which has more volatility and risk, CARM or ARDS?

Does the media refer more to CARM or ARDS?

Do analysts prefer CARM or ARDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools